Boston Scientific Corporation
NYSE:BSXMedical - Devices
+$0.45 today
- Market cap
- $63.25B
- Beta
- 0.56
- P/E (TTM)
- 19.0
- EPS (TTM)
- $2.39
Volume 13.21M
Average 19.45M
BSX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Boston Scientific CorporationNYSE: BSX
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents broadly unchanged from a year ago
Cash & equivalents stood at $539M at the end of Q2 FY2026, up 0.9% from a year earlier and down 64.6% from the prior quarter. Over 3 fiscal years it compounded at +30.1% a year.
Context
- Cash & equivalents amounted to 1.2% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +0.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 2.05B USD
- Year-over-year change
- +394.0%
- 4-year CAGR
- +1.5%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.05B | +394.0% |
| FY2024 | 2024-12-31 | 414M | -52.1% |
| FY2023 | 2023-12-31 | 865M | -6.8% |
| FY2022 | 2022-12-31 | 928M | -51.8% |
| FY2021 | 2021-12-31 | 1.93B | — |
Cash & Equivalents vs competitors
How BSX compares with its peers on the latest reported figures
- BSX's Jun 2026 cash & equivalents of $539M is the 4th highest of the 11 companies compared; the peer median is $186.53M.
- Its year-over-year change of +0.9% is the 4th highest of 11, against a peer median of -12.0%.
- Cash & equivalents amounts to 1.2% of total assets for BSX, versus a peer median of 14.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $2.91B | -11.2% | +56.3% | 21.0% | |
| Jul 2026 | $1.69B | +32.8% | +8.1% | 1.8% | |
| Sep 2026 | $563.5M | -12.8% | +43.7% | 20.8% | |
| Jun 2026 | $539M | +0.9% | +30.1% | 1.2% | |
| Jun 2026 | $300.16M | +18.3% | +10.4% | 4.4% | |
| Jun 2026 | $205.27M | -51.3% | +38.8% | 10.4% | |
| Jun 2026 | $167.79M | +42.4% | +42.3% | 24.8% | |
| Mar 2026 | $72.3M | -29.6% | -10.7% | 72.5% | |
| Feb 2026 | $37.81M | -15.5% | +24.7% | 14.5% | |
| Mar 2026 | $35.03M | -1.3% | +12.1% | 1.5% | |
| Sep 2026 | $0 | -100.0% | +97.3% | — | |
| Peer median (excluding BSX) | $186.53M | -12.0% | +31.8% | 14.5% | |
Competitors are the stored peer set for BSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.93B | 928M | 865M | 414M | 2.05B |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.78B | 1.97B | 2.23B | 2.56B | 2.93B |
| Inventory | 1.61B | 1.87B | 2.48B | 2.81B | 2.94B |
| Other Current Assets | 799M | 731M | 622M | 831M | 580M |
| Total Current Assets | 6.32B | 5.76B | 6.51B | 6.92B | 8.79B |
| Property, Plant & Equipment (Net) | 2.69B | 2.83B | 3.3B | 3.74B | 4.5B |
| Goodwill | 11.99B | 12.92B | 14.39B | 17.09B | 18.28B |
| Intangible Assets | 6.12B | 5.9B | 6B | 6.68B | 7.02B |
| Long-term Investments | 412M | 407M | 413M | 555M | 842M |
| Tax Assets | 4.14B | 3.94B | 3.84B | 3.66B | 3.68B |
| Other Non-current Assets | 563M | 707M | 680M | 749M | 559M |
| Total Non-current Assets | 25.91B | 26.71B | 28.62B | 32.48B | 34.88B |
| Total Assets | 32.23B | 32.47B | 35.14B | 39.4B | 43.67B |
| Account Payables | 794M | 862M | 942M | 960M | 1.14B |
| Short-term Debt | 261M | 20M | 531M | 1.78B | 389M |
| Tax Payables | 209M | 232M | 220M | 307M | 299M |
| Deferred Revenue | 208M | 220M | 266M | 306M | 313M |
| Other Current Liabilities | 629M | 1.64B | 1.92B | 491M | 2.17B |
| Total Current Liabilities | 4.27B | 3.8B | 4.93B | 6.4B | 5.44B |
| Long-term Debt | 8.8B | 8.91B | 8.57B | 8.84B | 11.46B |
| Deferred Tax Liabilities | 310M | 144M | 134M | 155M | 220M |
| Deferred Revenue (Non-current) | 276M | 289M | 311M | 329M | 369M |
| Other Non-current Liabilities | 1.55B | 1.4B | 1.27B | 1.14B | 1.14B |
| Total Non-current Liabilities | 11.33B | 11.09B | 10.67B | 10.99B | 13.76B |
| Total Liabilities | 15.61B | 14.9B | 15.61B | 17.39B | 19.2B |
| Common Stock | 17M | 17M | 17M | 17M | 17M |
| Retained Earnings | (1.39B) | (750M) | 819M | 2.67B | 5.57B |
| Accumulated OCI | 263M | 269M | 49M | 275M | (610M) |
| Other Stockholders Equity | 0 | 0 | 1M | 0 | 1M |
| Minority Interest | 0 | 0 | 248M | 233M | 239M |
| Total Equity | 16.62B | 17.57B | 19.53B | 22B | 24.47B |
| Total Debt | 9.45B | 9.28B | 9.49B | 11.15B | 12.42B |
| Net Debt | 7.53B | 8.35B | 8.63B | 10.73B | 10.37B |
Boston Scientific Corporation
NYSE:BSX
Intrinsic Alpha fair value
Locked
Current Price
$43.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.